Women with advanced cervical cancer -- the most common cancer afflicting young women -- are to get the first officially approved new treatment for
gives women around four months
Patients will have access via the Cancer Drugs Fund -LRB- CDF -RRB- until it is considered for routine NHS use
It has been available in England via the CDF since last March pending licensing
Each year an estimated 600 women with advanced cervical cancer could benefit from Avastin
